Patients with T2D taking incretin-based drugs do not face an increased risk for pancreatitis but have a modestly higher risk for biliary events than those on SGLT2 inhibitors.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/incretin-based-meds-may-modestly-raise-biliary-risk-t2d-2025a1000ytp?src=rss
Author :
Publish date : 2025-12-11 19:11:00
Copyright for syndicated content belongs to the linked Source.
